Human midsized neurofilament subunit induces motor neuron disease in transgenic mice.
Aberrant accumulation of neurofilaments is a feature of human motor neuron diseases. Experimentally motor neuron disease can be induced in transgenic mice by overexpressing the mouse neurofilament light subunit (NF-L), the human heavy subunit (NF-H), or mouse peripherin. Here we describe that mice harboring a bacterial artificial chromosome (BAC) transgene containing the human midsized neurofilament subunit (NF-M) gene develop a progressive hind limb paralysis associated with neurofilamentous accumulations in ventral horn motor neurons and axonal loss in ventral motor roots. Biochemical studies revealed that all three mouse neurofilament subunits along with the human NF-M contributed to filament formation, although filaments contained less peripherin. In addition the endogenous mouse NF-M became less phosphorylated in the presence of the human protein and accumulated in the cell bodies of affected neurons even though phosphorylated human NF-M did not. Remaining motor axons contained an increased density of neurofilaments and morphometric studies showed that principally small myelinated axons were lost in the transgenic animals. Removing half of the mouse NF-M by breeding the transgene onto the mouse NF-M heterozygous null background offered no protection against the development of disease, arguing that the effect is not simply due to elevation of total NF-M. Collectively these studies argue that the human and mouse NF-M proteins exhibit distinct biochemical properties and within mouse neurons are not interchangeable and that indeed the human protein may be toxic to some mouse neurons. These studies have implications for the use of human neurofilament transgenic mice as models of amyotrophic lateral sclerosis.
Gama Sosa
Miguel A
MA
Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA.
Friedrich
Victor L
VL
DeGasperi
Rita
R
Kelley
Kevin
K
Wen
Paul H
PH
Senturk
Emir
E
Lazzarini
Robert A
RA
Elder
Gregory A
GA
D000818:Animals; D001369:Axons / Q000648:ultrastructure; D015153:Blotting, Western; D048429:Cell Size; D005455:Fluorescent Antibody Technique; D006614:Hindlimb / Q000503:physiopathology; D006801:Humans; D002479:Inclusion Bodies / Q000473:pathology; D007381:Intermediate Filament Proteins / Q000096:biosynthesis / Q000235:genetics; D008562:Membrane Glycoproteins; D051379:Mice; D008822:Mice, Transgenic; D008854:Microscopy, Electron; D016472:Motor Neuron Disease / Q000235:genetics* / Q000378:metabolism; D009046:Motor Neurons / Q000473:pathology; D009419:Nerve Tissue Proteins / Q000096:biosynthesis / Q000235:genetics; D016900:Neurofilament Proteins / Q000096:biosynthesis* / Q000235:genetics* / Q000378:metabolism; D010243:Paralysis / Q000139:chemically induced / Q000235:genetics / Q000503:physiopathology; D064531:Peripherins; D010766:Phosphorylation
D007381:Intermediate Filament Proteins; D008562:Membrane Glycoproteins; D009419:Nerve Tissue Proteins; D016900:Neurofilament Proteins; C578994:PRPH protein, human; D064531:Peripherins; C044882:neurofilament protein L